Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease

A Ansari, Cesare Hassan, J Duley, A Marinaki, E Shobowale Bakre, P Seed, J Meenan, A Yim, J. Sanderson

Research output: Contribution to journalArticle

221 Citations (Scopus)

Abstract

Azathioprine therapy is discontinued in one-third of patients with inflammatory bowel disease because of toxicity or a lack of clinical response. Patients with thiopurine methyltransferase (TPMT) deficiency are intolerant to azathioprine, whilst carriers are at increased risk of side-effects.
Original languageEnglish
Pages (from-to)1743-1750
Number of pages8
JournalALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume16
Publication statusPublished - 2002
Externally publishedYes

Keywords

  • Adult
  • Azathioprine
  • Biological Markers
  • Erythrocytes
  • Female
  • Genotype
  • Humans
  • Immunosuppressive Agents
  • Inflammatory Bowel Diseases
  • Leukocyte Count
  • Logistic Models
  • Male
  • Methyltransferases
  • Middle Aged
  • Odds Ratio
  • Retrospective Studies
  • Treatment Failure

Fingerprint

Dive into the research topics of 'Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this